Glioblastoma Multiforme Treatment (GBM) Market: Current Analysis and Forecast (2022-2030)

Glioblastoma Multiforme Treatment (GBM) Market: Current Analysis and Forecast (2022-2030)

Glioblastoma multiforme (GBM) is a type of aggressive brain cancer that develops from glial cells, which are cells that support and protect nerve cells in the brain. It is the most common and malignant form of primary brain tumor, accounting for about 15% of all brain tumors. The increasing prevalence of the glioblastoma multiforme is the major factor responsible for the market growth of the glioblastoma multiforme treatment market. For instance, As per the National Brain Tumor Society, GBM accounts for 49.1% of all primary malignant brain tumors. It is estimated that more than 10,000 people die from glioblastoma each year in the United States.

Glioblastoma Multiforme Treatment (GBM) Market is expected to grow at a strong CAGR of 8% during the forecast period owing to favorable governmental policies on brain cancer treatment. For instance, in December 2022, The Australian Brain Tumor Mission invested USD 136.66 million to support brain tumor research. The goal is to double survival rates and improve the quality of life for brain tumor patients.

• Based on treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating Field (TTF) therapy, and immunotherapy. The radiation therapy segment acquired a major share in 2021. Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It is often used in combination with other treatments, such as surgery and chemotherapy, to improve the chances of success. The increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced radiation therapy technologies are the major attributing factor to the considerable share of radiation therapy in the GBM treatment market.
• Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The clinics segment is expected to grow with the highest CAGR during the forecast period. The clinics in the GBM treatment market offer a variety of services, including imaging and diagnostic tests to confirm the presence of GBM, surgical procedures to remove tumors, radiation therapy to kill cancer cells, and chemotherapy to destroy cancer cells that have spread to other parts of the body are the main reason for the segmental growth.
• For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America is a significant market for glioblastoma multiforme treatment. This is mainly due to the high prevalence of glioblastoma, along with the presence of the well-established infrastructure in the region attributes to the significant growth of the region in the glioblastoma multiforme treatment in the region. , with a growing number of people seeking out alternative and complementary therapies to supplement their conventional healthcare. Further, the region is also witnessing an increasing number of hospitals catering to integrative therapies also attributes to the growth of the market in the region. For instance, as per the National Brain Tumor Society, more than 13,000 Americans were diagnosed with glioblastoma multiforme in 2022.
• Some of the major players operating in the market include Merck & Co., Inc.; Amgen Inc.; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Karyopharm; Sumitomo Pharma Oncology, Inc; and Bristol-Myers Squibb Company.